What is Exploramed?
Exploramed operates as a specialized medical device incubator, functioning as a catalyst for the creation of high-value healthcare solutions. By identifying persistent clinical problems, the firm develops patient-driven technologies that prioritize both quality of life and economic efficiency. With a proven track record of launching eight distinct companies, Exploramed serves as a bridge between raw medical innovation and market-ready commercialization. Its market position is defined by a unique collaborative model, partnering with industry leaders to refine and deploy cutting-edge devices that challenge the status quo of medical intervention.
How much funding has Exploramed raised?
Exploramed has raised a total of $47.5M across 3 funding rounds:
Private Equity
$18.5M
Private Equity
$14M
Private Equity
$15M
Private Equity (2008): $18.5M with participation from Morgenthaler Partners and NEA
Private Equity (2014): $14M led by New Enterprise Associates
Private Equity (2015): $15M supported by NEA
Key Investors in Exploramed
Morgenthaler Partners
Morgenthaler is a premier venture capital and private equity firm with over 40 years of experience in creating valuable companies, specializing in investments within the Information Technology and Life Sciences sectors.
New Enterprise Associates
Established in 1977, New Enterprise Associates is a global venture capital firm focused on helping entrepreneurs build transformative businesses across various stages of growth.
NEA
NEA is a prominent venture capital firm that provides strategic backing to early and growth-stage companies, with a significant emphasis on the healthcare and technology sectors.
What's next for Exploramed?
Looking ahead, Exploramed is poised to leverage its recent capital injection to accelerate the development pipeline of its current portfolio and potentially expand its incubator footprint. The strategic focus remains on scaling existing device solutions while identifying new opportunities within the life sciences sector that require a sophisticated, patient-first approach. As the firm continues to navigate the complexities of the medical technology market, its emphasis on cost-effective, high-quality outcomes will likely remain the primary driver of its long-term value creation and future financing rounds.
See full Exploramed company page
